XKON/086220 (XKON/086220)

Korea New Exchange: XKON/086220 · KRW

₩1,190

+95.00 (+8.7%)· Recorded snapshot

Market cap	15.1B
Revenue (ttm)	38.1B
Net income (ttm)	-323.5M
EPS (ttm)	-₩57.0
Shares out	12.7M
Volume	101
Beta	-0.01

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 38.1B
Net income (ttm): -323.5M
EPS (ttm): -₩57.0
Market cap: 15.1B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-4.1

P25 n/aP50 n/aP75 n/a

ROIC3.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All XKON/086220 indicators

Market & fundamental data

Available fields

175

Groups with data

Currency

KRW

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	KRW
Country	South Korea
Country code	KR
Employees	81
Exchange	Korea New Exchange
Financial currency	KRW
Financial report date	2012-12-31
First seen	2026-05-10
Fiscal year end	December
Founded	1992
Industry	Pharmaceutical Preparations
Is primary listing	Yes
ISIN number	KR7086220001
Last refreshed	2026-10-28
Market cap	KRW 15.1B
Price	KRW 1,190.00
Price currency	KRW
SIC code	2834
Stock price date	2026-10-28
Symbol	xkon/086220
Website	https://www.kdhealthbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-4.79%
FCF yield	2.32%
Industry P/E	26.13x
P/B ratio	1.28x
P/FCF ratio	43.11x
P/OCF ratio	25.88x
P/S ratio	0.4x
Price / tangible book value	1.32x
Price/EBITDA ratio	5.69x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	2.69%
EBITDA margin	6.97%
FCF margin	0.92%
Gross margin	13.27%
Operating margin	2.69%
Pretax margin	-0.73%
Profit margin	-0.85%
Profit per employee	KRW -4M
Revenue per employee	KRW 470.3M
ROA	1.62%
ROA (5Y)	2.21%
ROCE	7.35%
ROE	-4.15%
ROE (5Y)	-3.48%
ROIC	3.4%
ROIC (5Y)	3.87%
Tax / revenue	0.12%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
FCF growth 3Y	-39.21%
Gross profit growth	-20%
Gross profit growth 3Y	-12.73%
Gross profit growth 5Y	0.58%
OCF growth 3Y	-32.72%
Operating income growth	-68.3%
Operating income growth 3Y	-22.07%
Operating income growth 5Y	-0.7%
Revenue growth	-2.5%
Revenue growth 3Y	-7.21%
Revenue growth 5Y	5.48%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	KRW -233.2M
Depreciation and amortization	KRW 1.6B
EBIT	KRW 1B
EBITDA	KRW 2.7B
EPS	KRW -57.00
FCF per share	KRW 27.61
Financing cash flow	KRW 828.3M
Free cash flow	KRW 350.3M
Gross profit	KRW 5.1B
Income taxes	KRW 45.8M
Investing cash flow	KRW -392.4M
Net borrowing	KRW -7.6B
Net cash flow	KRW 1B
Net income	KRW -323.5M
Operating income	KRW 1B
Revenue	KRW 38.1B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.77
Book value per share	KRW 2,084.52
Debt / EBITDA	7.33
Debt / equity	1.64
Debt / FCF	55.56
Interest coverage	1.07
Long-term assets	KRW 27.2B
Long-term liabilities	KRW -6B
Net cash (debt)	KRW -18.2B
Net cash / market cap	-120.42%
Net debt / EBITDA	6.85
Net debt / equity	1.54
Net debt / FCF	51.91
Piotroski F-Score	3
Property, plant and equipment	KRW 24.1B
Shareholders' equity	KRW 11.8B
Tangible book value	KRW 11.4B
Tangible book value per share	KRW 2,009.91
Total assets	KRW 39.3B
Total cash	KRW 1.3B
Total debt	KRW 19.5B
Total liabilities	KRW 27.4B
WACC	4.02%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.96
Current assets	KRW 12.1B
Current liabilities	KRW 33.4B
Current ratio	0.52
Inventory turnover	6.5
Net working capital	KRW 5.2B
Quick ratio	0.22
Working capital	KRW -12B
Working capital turnover	-2.62

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	33.03%
Shareholder yield	33.03%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	KRW 1,147.81
1D price change	8.68%
1M price change	25.86%
1M total return	25.86%
1W price change	-8.67%
1W total return	-8.67%
1Y price change	-12.05%
1Y return CAGR	-12.06%
1Y total return	-12.05%
20-day SMA	KRW 1,107.15
200-day SMA	KRW 1,216.55
3M price change	78.05%
3M total return	78.05%
3Y price change	-60.89%
3Y return CAGR	-26.87%
3Y total return	-60.89%
50-day SMA	KRW 1,003.40
50-day SMA vs 200-day SMA	50under200
52-week high	KRW 1,719.00
52-week high date	2025-12-09
52-week low	KRW 600.00
52-week low date	2026-07-29
5Y price change	-63.32%
5Y return CAGR	-18.18%
5Y total return	-63.32%
6M price change	-20.01%
6M total return	-20.01%
All-time high	KRW 6,020.00
All-time high date	2018-02-08
All-time low	KRW 600.00
All-time low date	2026-07-21
Average true range (ATR)	KRW 108.24
Average volume	257.6
Beta (1Y)	0.83
Beta (2Y)	0.65
Beta (5Y)	-0.01
Change from 52-week high	-30.77%
Change from 52-week low	98.33%
Change from all-time high	-81.81%
Change from all-time low	82.5%
Change from open	8.68%
Day's gap	0%
Dollar volume	KRW 120,190
High price	KRW 1,198.00
Low price	KRW 1,095.00
Monthly RSI	37.92
Open price	KRW 1,095.00
Position in 52-week range	92.23%
Previous close	KRW 1,095.00
Price vs 150-day SMA	-4.6%
Price vs 20-day SMA	-1.1%
Price vs 200-day SMA	-9.99%
Price vs 50-day SMA	9.13%
Relative volume	0.39
RSI	51.32
Sharpe ratio	0
Sharpe ratio (3Y)	0.12
Sharpe ratio (5Y)	0.13
Sortino ratio	0.07
Sortino ratio (3Y)	0.24
Sortino ratio (5Y)	0.26
Volume	101
Weekly RSI	48.76
YTD price change	-30.43%
YTD total return	-30.43%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2.6M
Shares outstanding	12.7M

Deeper analysis on XKON/086220

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XKON/086220 report

Is a complete XKON/086220 research report available?

No complete published report is available for xkon/086220 (XKON/086220) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

XKON/086220 (XKON/086220)

Price

Financial snapshot

Fair-value bridge

Latest news · XKON/086220

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XKON/086220 indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XKON/086220

Frequently asked questions